QS-21
- Generic Name
- QS-21
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 61H83WZX3U
- Background
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of dis...
- Indication
Investigated for use/treatment in genital herpes, HIV infection, hepatitis (viral, B), influenza, malaria, melanoma, and viral infection.
- Associated Conditions
- -
- Associated Therapies
- -
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05638698
- Locations
- 🇺🇸
University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
🇺🇸University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.